PreComb Therapeutics

PreComb Therapeutics

Basel, Switzerland· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.8M

Overview

PreComb Therapeutics is a private, pre-revenue company based in Basel, Switzerland, offering a high-throughput, automated functional profiling platform for oncology. Its 3DTwin® system screens patient-derived tumor models against various therapies to predict drug response dynamics, supporting critical development decisions like candidate prioritization and combination design. The company positions itself as a translational research partner, aiming to reduce downstream clinical trial failure risk by providing more clinically predictive data earlier in the drug development process.

Oncology

Technology Platform

3DTwin® Dynamic Drug Response Screening: A high-throughput, automated platform using patient-derived 3D microtumors for longitudinal functional profiling of drug response, adaptation, and resistance dynamics.

Funding History

1
Total raised:$2.8M
Seed$2.8M

Opportunities

The high failure rate and cost of oncology drug development create a strong demand for more predictive preclinical tools.
The industry's shift towards complex combination therapies further amplifies the need for platforms that can efficiently test for synergy and resistance.

Risk Factors

Key risks include the need to clinically validate that platform data correlates with patient outcomes, competition from other advanced model providers, and the challenge of scaling operations and convincing pharma to adopt a new service.
As a pre-revenue company, it also faces funding risk.

Competitive Landscape

PreComb competes in the translational oncology tools market against providers of patient-derived organoid (PDO) services, patient-derived xenograft (PDX) models, and other functional diagnostic platforms. Differentiation is claimed through longitudinal, high-throughput, automated profiling of dynamic response and resistance.